Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Upstream Bio, Inc.

Ticker
UPB
Sector
Industry
Report date
November 10, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news highlights Upstream Bio's quarterly financial results showing losses with some revenue performance, ongoing clinical trial progress, and upcoming Phase 3 trial plans.

Recent developments:
  • Upstream Bio reported a net loss in Q3 2026 and revenue below prior reported figures [N1].
  • The company posted a narrower loss in Q2 2026 and has ongoing Phase 2 readouts for verekitug planned in the second half of 2027 [N3].
  • Q2 2026 results showed a loss but revenue performance exceeded some prior figures [N4].
  • Q1 2026 results included a loss but revenue performance exceeded some prior figures [N6].
  • Positive clinical improvements were presented from the Phase 2 VIBRANT trial on verekitug in June 2026 [N5].
Overview

Upstream Bio, Inc. focuses on developing treatments for inflammatory diseases, with an emphasis on severe respiratory disorders. Its lead candidate, verekitug, is a novel monoclonal antibody that inhibits the TSLP receptor, a validated target in inflammatory pathways. The company has conducted multiple clinical trials, including Phase 2 studies in severe asthma, CRSwNP, and COPD, reporting positive top-line results in severe asthma and CRSwNP. Verekitug is distinguished by its high potency and potential for extended dosing intervals, aiming to improve patient outcomes and reduce treatment burden. The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in early 2027 and is advancing its COPD program. Upstream Bio maintains strong liquidity with substantial cash and investments as of Q3 2026 and continues to report operating losses consistent with its clinical-stage status.

Executive summary

Upstream Bio, Inc. is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody targeting the TSLP receptor for severe respiratory inflammatory diseases including severe asthma, CRSwNP, and COPD. The company has reported positive Phase 2 clinical trial results and plans to initiate Phase 3 trials in early 2027. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, the company held $47.4 million in cash and equivalents and $159.9 million in short-term investments, with strong liquidity ratios and a net loss of $41.2 million for the quarter [S1][S2].

Scenarios for UPB

Bull case model:

Upstream Bio's clinical data indicate that verekitug has a unique mechanism of action with high potency and extended dosing intervals, which could address unmet needs in severe respiratory diseases. Positive Phase 2 trial results in severe asthma and CRSwNP support regulatory submission efforts. The planned initiation of Phase 3 trials in early 2027 represents a key execution milestone. Strong liquidity provides financial flexibility to advance clinical programs. The company's strategy to develop a broadly applicable therapy without biomarker restrictions and enable quarterly at-home administration may enhance patient adherence and market acceptance.

Bear case model:

As a clinical-stage biotechnology company, Upstream Bio faces risks inherent to drug development, including the possibility that ongoing and future clinical trials may not replicate earlier positive results or demonstrate sufficient safety and efficacy for regulatory approval. The company currently reports operating losses and depends on continued financing to support its development programs. Competition from existing biologics and other emerging therapies targeting similar pathways may impact market potential. Regulatory, manufacturing, and commercialization challenges also pose risks to the company's ability to successfully bring verekitug to market.

Moat:

Upstream Bio's moat is centered on its proprietary development of verekitug, the only known monoclonal antibody antagonist targeting the TSLP receptor, which is upstream in the inflammatory cascade and potentially offers broader efficacy and extended dosing intervals compared to existing therapies targeting downstream cytokines or the TSLP ligand. The company's clinical data demonstrating high potency and sustained biomarker reductions, combined with a differentiated dosing schedule, may provide competitive advantages in treating severe asthma, CRSwNP, and COPD. Additionally, the company's experienced leadership team and ongoing clinical development pipeline contribute to its strategic positioning in a market with significant unmet medical needs.

Risks overview
Risks summary
The primary risk for Upstream Bio is the uncertainty inherent in clinical development and regulatory approval of its lead product candidate, verekitug, which may impact its ability to commercialize and generate revenue.
Risks details:

• Clinical Development Risk: Future clinical trials may not confirm the safety and efficacy of verekitug observed in earlier phases, potentially delaying or preventing regulatory approval.
• Financial Risk: The company reports ongoing net losses and relies on sufficient capital to fund its clinical programs and operations.
• Competitive Risk: Existing approved biologics and other therapies targeting inflammatory pathways may limit market adoption of verekitug.
• Regulatory Risk: Approval processes and regulatory requirements may pose challenges and delays in bringing verekitug to market.

FINAL FORECAST FOR UPB

Final take one line
Upstream Bio is a clinical-stage biotech company with detailed clinical development and financial disclosures, showing strong liquidity and ongoing progress in respiratory disease therapeutics.
Final take 12 to 24 month view

Business trends: Continued clinical development of verekitug with positive Phase 2 results and initiation of Phase 3 trials for severe asthma and CRSwNP.
Execution milestones: Completion of Phase 3 trial dosing initiation in early 2027 and readouts from Phase 2 COPD trials.
Key risks: Clinical trial outcomes, regulatory approval challenges, financial sustainability, and competitive pressures in respiratory biologics.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, primarily severe respiratory disorders such as severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD) [S1].
  • The company's lead product candidate is verekitug, a monoclonal antibody that targets and inhibits the TSLP receptor, a cytokine receptor involved in inflammatory responses [S1].
  • Verekitug is the only known antagonist in clinical development targeting the TSLP receptor, distinct from tezepelumab which targets the TSLP ligand [S1].
  • Preclinical and clinical data indicate verekitug is highly potent, approximately 300-fold more potent than tezepelumab, with potential for extended dosing intervals up to 24 weeks [S1].
  • Upstream Bio has conducted multiple clinical trials for verekitug, including Phase 1b multiple ascending dose (MAD) trials, Phase 2 trials in severe asthma, CRSwNP, and COPD, and a long-term safety and efficacy extension study (Phase 2 LTE) [S1].
  • Positive top-line results were reported from the Phase 2 CRSwNP trial in September 2025 and the Phase 2 severe asthma trial in February 2026 [S1].
  • The company initiated a Phase 2 COPD trial in July 2025 and plans to start Phase 3 trials for severe asthma and CRSwNP in the first quarter of 2027 [S1].
  • Verekitug has shown rapid and sustained target engagement and biomarker reductions in asthma patients, with a favorable safety and pharmacokinetic profile across approximately 500 participants treated in clinical trials [S1].
  • The company’s strategy includes leveraging verekitug’s unique mechanism to address unmet needs in severe inflammatory diseases with a focus on maximizing efficacy without biomarker restriction and enabling quarterly at-home administration [S1].
  • Severe asthma affects 5-10% of asthma patients, with a large unmet need despite existing biologics; CRSwNP and COPD also represent significant patient populations with unmet treatment needs [S1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $47.4 million, short-term investments of $159.9 million, current assets of $244.6 million, and current liabilities of $11.96 million, resulting in a current ratio of 20.45 and a cash ratio of 17.34, indicating strong liquidity [S2].
  • The company reported a net loss of $41.2 million and basic and diluted EPS of -$0.75 for the quarter ended September 30, 2026 [S2].
  • Recent quarterly reports show losses but some revenue estimates were topped in Q2 and Q1 2026, with narrowing losses reported in Q2 2026 [N6][N4][N3][N1].
  • The company’s leadership team has significant experience in developing and commercializing medicines for severe asthma and respiratory diseases [S1].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/upstream-bio-inc-upb-reports-q3-loss-lags-revenue-estimates
  • N2 | 2026-11-02 | www.nasdaq.com | Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/syndax-pharmaceuticals-sndx-reports-q3-loss-beats-revenue-estimates
  • N3 | 2026-08-13 | www.nasdaq.com | Upstream Posts Narrower Loss In Q2; Expects Phase 2 Readouts For Verekitug In H2 2027 | https://www.nasdaq.com/articles/upstream-posts-narrower-loss-q2-expects-phase-2-readouts-verekitug-h2-2027
  • N4 | 2026-08-11 | www.nasdaq.com | Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/upstream-bio-inc-upb-reports-q2-loss-tops-revenue-estimates
  • N5 | 2026-06-15 | www.nasdaq.com | Upstream Bio Presents Clinically Meaningful Improvements In Phase 2 VIBRANT Trial On Verekitug | https://www.nasdaq.com/articles/upstream-bio-presents-clinically-meaningful-improvements-phase-2-vibrant-trial-verekitug
  • N6 | 2026-05-13 | www.nasdaq.com | Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/upstream-bio-inc-upb-reports-q1-loss-beats-revenue-estimates
  • N7 | 2026-04-30 | www.nasdaq.com | Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-tops-q1-earnings-and-revenue-estimates
  • N8 | 2026-02-13 | www.nasdaq.com | Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace | https://www.nasdaq.com/articles/weekly-buzz-fda-okays-nvcrs-cancer-device-rgnx-gets-crlonco-buy-xbot-phios-ph-762-sets
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine